Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Type (Immunology, Oncology), By Technology (Cell-based flow cytometry, Bead-based Flow Cytometry), By Offering (Reagents, Instruments, and Consumables Software), By Application (Translational Research, Clinical Research), By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others), By Region
Global Flow Cytometry in Oncology and Immunology Market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. This can be ascribed due to the expansion of flow cytometry’s applicability in research activities and the development of next-generation flow cytometers. According to the World Health Organization, Cancer is one of the leading causes of disease burden and mortality in the world, and strategies for cancer prevention, diagnosis, and treatment are still a global effort. Flow cytometry in oncology and immunology refers to the laboratory procedure to measure the number of cells, the percentage of live cells, and certain characteristics of cells, such as size and shape, in a sample of blood, bone marrow, or other tissue, the presence of tumor markers, such as antigens, on the surface of the cells. Immuno-oncology (IO) is the study of the immune system's functionality against cancer and the development of treatments that improve the ability of the immune system to fight the disease. However, the demand for new oncology and immunologic techniques/tools is increasing, which is further expected to drive the growth of global flow cytometry in the oncology and immunology market. Additionally, the development of technology and efforts to find specific and sensitive tools to monitor immune responses during and after therapy is thereby expected to drive the growth of the market in the forecast years.
The growing prevalence of cancer cases, the technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. However, the high cost of products of flow cytometry equipment is expected to hamper the growth of flow cytometry in the oncology and immunology market in the forecast years.
Rising Prevalence of Cancer Cases
Globally, Cancer is one of the prevalent causes of death. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's expansion. In the United States of America in 2021, there were 1.8 million new cases and 0.6 million cancer deaths, according to the American Cancer Society.
Medical professionals are stepping up their research and development efforts to create therapies and diagnostic services as a result of the expansion of malignant cells to aid the prevention and treatment of cancer. Cancer immunotherapy is becoming the standard of care for multiple tumor types at diverse disease stages, providing better survival with reduced disease recurrences. According to Food and Drug Administration (FDA), multiple clinical trials with successful implementation of immunology and oncology treatments are being conducted to evaluate the efficacy of treatments of multiple cancer types, to implement combinatorial therapies, to gain mechanistic insight for new drug development or to identify immune predictors of clinical response. Therefore, their treatment and developed therapies are responsible for propelling the growth of global flow cytometry in the oncology and immunology market.
Advancement in Technology
The development of more advanced technologies includes mass cytometry, imaging flow cytometry, genomic cytometry, and spectral cytometry with an expanded ability to study immune responses by characterizing more cellular parameters simultaneously in single cells with higher resolution. According to the researchers, the immune system can target and destroy cancer cells; therefore, immune-oncology-based therapies cover different approaches to boost the immune response in cancer patients, that range from activation of effector cells, vaccination with tumor antigens, administration of oncolytic viruses, blockage of inhibitory pathways or immunosuppressive mechanisms, use of adoptive chimeric antigen receptor T-cell therapy, and to amplify the protective pathways.
Recent Developments & Product Launches
The growth of global flow cytometry in the oncology and immunology market is witnessed due to the presence of major market players. For instance, in June 2022, Becton, Dickinson, and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). In September 2022, a company, namely Becton, Dickinson, launched BD Research Cloud, a cloud-based software solution designed to improve the flow cytometry process for researchers working in a variety of fields, such as immunology, virology, cancer, and infectious disease monitoring, in order to enable higher-quality experiments with faster time to understand. Additionally, in February 2022, Becton, Dickinson acquired Cytognos, S.L. and expanded its flow cytometry portfolio, and gained the expertise of ~80 scientists and professionals at Cytognos S.L.
Market Segmentation
Global Flow Cytometry in Oncology and Immunology Market can be segmented by type, technology, offering, application, end user, region, and company. Based on type, the market can be segmented into immunology and oncology. Based on technology, the market is fragmented into cell-based flow cytometry and bead-based flow cytometry. Based on the offering, the market is segmented into reagents, instruments, and consumables software. Based on application, the market is fragmented into translational research and clinical research. Based on end users, the market is segmented into hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, and others.
Company Profiles
Danaher Corporation, Merck KGaA, Miltenyi Biotec, Neo-Genomics Laboratories, Inc., Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Agilent Technologies, Inc., DiaSorin S.p.A (Luminex Corporation), OPKO Health, Inc., etc., are some of the key players operating in the global flow cytometry in the oncology and immunology market.
Report Scope:
In this report, Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology and Immunology Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
The growing prevalence of cancer cases, the technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. However, the high cost of products of flow cytometry equipment is expected to hamper the growth of flow cytometry in the oncology and immunology market in the forecast years.
Rising Prevalence of Cancer Cases
Globally, Cancer is one of the prevalent causes of death. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's expansion. In the United States of America in 2021, there were 1.8 million new cases and 0.6 million cancer deaths, according to the American Cancer Society.
Medical professionals are stepping up their research and development efforts to create therapies and diagnostic services as a result of the expansion of malignant cells to aid the prevention and treatment of cancer. Cancer immunotherapy is becoming the standard of care for multiple tumor types at diverse disease stages, providing better survival with reduced disease recurrences. According to Food and Drug Administration (FDA), multiple clinical trials with successful implementation of immunology and oncology treatments are being conducted to evaluate the efficacy of treatments of multiple cancer types, to implement combinatorial therapies, to gain mechanistic insight for new drug development or to identify immune predictors of clinical response. Therefore, their treatment and developed therapies are responsible for propelling the growth of global flow cytometry in the oncology and immunology market.
Advancement in Technology
The development of more advanced technologies includes mass cytometry, imaging flow cytometry, genomic cytometry, and spectral cytometry with an expanded ability to study immune responses by characterizing more cellular parameters simultaneously in single cells with higher resolution. According to the researchers, the immune system can target and destroy cancer cells; therefore, immune-oncology-based therapies cover different approaches to boost the immune response in cancer patients, that range from activation of effector cells, vaccination with tumor antigens, administration of oncolytic viruses, blockage of inhibitory pathways or immunosuppressive mechanisms, use of adoptive chimeric antigen receptor T-cell therapy, and to amplify the protective pathways.
Recent Developments & Product Launches
The growth of global flow cytometry in the oncology and immunology market is witnessed due to the presence of major market players. For instance, in June 2022, Becton, Dickinson, and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). In September 2022, a company, namely Becton, Dickinson, launched BD Research Cloud, a cloud-based software solution designed to improve the flow cytometry process for researchers working in a variety of fields, such as immunology, virology, cancer, and infectious disease monitoring, in order to enable higher-quality experiments with faster time to understand. Additionally, in February 2022, Becton, Dickinson acquired Cytognos, S.L. and expanded its flow cytometry portfolio, and gained the expertise of ~80 scientists and professionals at Cytognos S.L.
Market Segmentation
Global Flow Cytometry in Oncology and Immunology Market can be segmented by type, technology, offering, application, end user, region, and company. Based on type, the market can be segmented into immunology and oncology. Based on technology, the market is fragmented into cell-based flow cytometry and bead-based flow cytometry. Based on the offering, the market is segmented into reagents, instruments, and consumables software. Based on application, the market is fragmented into translational research and clinical research. Based on end users, the market is segmented into hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, and others.
Company Profiles
Danaher Corporation, Merck KGaA, Miltenyi Biotec, Neo-Genomics Laboratories, Inc., Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Agilent Technologies, Inc., DiaSorin S.p.A (Luminex Corporation), OPKO Health, Inc., etc., are some of the key players operating in the global flow cytometry in the oncology and immunology market.
Report Scope:
In this report, Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Flow Cytometry in Oncology and Immunology Market, By Type:
- Immunology
- Oncology
- Flow Cytometry in Oncology and Immunology Market, By Technology:
- Cell-based flow cytometry
- Bead-based flow cytometry
- Flow Cytometry in Oncology and Immunology Market, By Offering:
- Reagents
- Instruments
- Consumables software
- Flow Cytometry in Oncology and Immunology Market, By Application:
- Translational Research
- Clinical Research
- Flow Cytometry in Oncology and Immunology Market, By End User:
- Hospitals
- Diagnostic Laboratories
- Reference Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations
- Others
- Flow Cytometry in Oncology and Immunology Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology and Immunology Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Immunology, Oncology)
5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
5.2.4. By Application (Translational Research, Clinical Research)
5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
5.2.7. By Company (2022)
5.3. Market Map
5.3.1. By Type
5.3.2. By Technology
5.3.3. By Offering
5.3.4. By Application
5.3.5. By End User
5.3.6. By Region
6. NORTH AMERICA FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Technology
6.2.3. By Offering
6.2.4. By Application
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Offering
6.3.1.2.4. By Application
6.3.1.2.5. By End User
6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Offering
6.3.2.2.4. By Application
6.3.2.2.5. By End User
6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Offering
6.3.3.2.4. By Application
6.3.3.2.5. By End User
7. EUROPE FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Technology
7.2.3. By Offering
7.2.4. By Application
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Offering
7.3.1.2.4. By Application
7.3.1.2.5. By End User
7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Offering
7.3.2.2.4. By Application
7.3.2.2.5. By End User
7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Offering
7.3.3.2.4. By Application
7.3.3.2.5. By End User
7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Offering
7.3.4.2.4. By Application
7.3.4.2.5. By End User
7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Offering
7.3.5.2.4. By Application
7.3.5.2.5. By End User
8. ASIA-PACIFIC FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Technology
8.2.3. By Offering
8.2.4. By Application
8.2.5. By End User
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Offering
8.3.1.2.4. By Application
8.3.1.2.5. By End User
8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Offering
8.3.2.2.4. By Application
8.3.2.2.5. By End User
8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Offering
8.3.3.2.4. By Application
8.3.3.2.5. By End User
8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Offering
8.3.4.2.4. By Application
8.3.4.2.5. By End User
8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Offering
8.3.5.2.4. By Application
8.3.5.2.5. By End User
9. SOUTH AMERICA FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Technology
9.2.3. By Offering
9.2.4. By Application
9.2.5. By End User
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Offering
9.3.1.2.4. By Application
9.3.1.2.5. By End User
9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Offering
9.3.2.2.4. By Application
9.3.2.2.5. By End User
9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Offering
9.3.3.2.4. By Application
9.3.3.2.5. By End User
10. MIDDLE EAST AND AFRICA FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Technology
10.2.3. By Offering
10.2.4. By Application
10.2.5. By End User
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Offering
10.3.1.2.4. By Application
10.3.1.2.5. By End User
10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Offering
10.3.2.2.4. By Application
10.3.2.2.5. By End User
10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Offering
10.3.3.2.4. By Application
10.3.3.2.5. By End User
10.3.4. Turkey Flow Cytometry in Oncology and Immunology Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Type
10.3.4.2.2. By Technology
10.3.4.2.3. By Offering
10.3.4.2.4. By Application
10.3.4.2.5. By End User
10.3.5. Egypt Flow Cytometry in Oncology and Immunology Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Type
10.3.5.2.2. By Technology
10.3.5.2.3. By Offering
10.3.5.2.4. By Application
10.3.5.2.5. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.1.1. Rising Prevalence of Cancer Cases
11.1.2. Advancement in Technology
11.1.3. Recent Developments & Product Launches
11.2. Challenges
11.2.1. High Cost of the Products of the Flow Cytometry Equipment
11.2.2. False antibody responses
12. MARKET TRENDS & DEVELOPMENTS
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.5.1. Danaher Corporation
13.5.2. Merck KGaA
13.5.3. Miltenyi Biotec
13.5.4. Neo-Genomics Laboratories, Inc.
13.5.5. Thermo Fisher Scientific Inc
13.5.6. Cell Signaling Technology, Inc
13.5.7. Becton, Dickinson and Company
13.5.8. Agilent Technologies, Inc.
13.5.9. DiaSorin S.p.A (Luminex Corporation)
13.5.10. OPKO Health, Inc.
14. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Immunology, Oncology)
5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
5.2.4. By Application (Translational Research, Clinical Research)
5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
5.2.7. By Company (2022)
5.3. Market Map
5.3.1. By Type
5.3.2. By Technology
5.3.3. By Offering
5.3.4. By Application
5.3.5. By End User
5.3.6. By Region
6. NORTH AMERICA FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Technology
6.2.3. By Offering
6.2.4. By Application
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Offering
6.3.1.2.4. By Application
6.3.1.2.5. By End User
6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Offering
6.3.2.2.4. By Application
6.3.2.2.5. By End User
6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Offering
6.3.3.2.4. By Application
6.3.3.2.5. By End User
7. EUROPE FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Technology
7.2.3. By Offering
7.2.4. By Application
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Offering
7.3.1.2.4. By Application
7.3.1.2.5. By End User
7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Offering
7.3.2.2.4. By Application
7.3.2.2.5. By End User
7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Offering
7.3.3.2.4. By Application
7.3.3.2.5. By End User
7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Offering
7.3.4.2.4. By Application
7.3.4.2.5. By End User
7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Offering
7.3.5.2.4. By Application
7.3.5.2.5. By End User
8. ASIA-PACIFIC FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Technology
8.2.3. By Offering
8.2.4. By Application
8.2.5. By End User
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Offering
8.3.1.2.4. By Application
8.3.1.2.5. By End User
8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Offering
8.3.2.2.4. By Application
8.3.2.2.5. By End User
8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Offering
8.3.3.2.4. By Application
8.3.3.2.5. By End User
8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Offering
8.3.4.2.4. By Application
8.3.4.2.5. By End User
8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Offering
8.3.5.2.4. By Application
8.3.5.2.5. By End User
9. SOUTH AMERICA FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Technology
9.2.3. By Offering
9.2.4. By Application
9.2.5. By End User
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Offering
9.3.1.2.4. By Application
9.3.1.2.5. By End User
9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Offering
9.3.2.2.4. By Application
9.3.2.2.5. By End User
9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Offering
9.3.3.2.4. By Application
9.3.3.2.5. By End User
10. MIDDLE EAST AND AFRICA FLOW CYTOMETRY IN ONCOLOGY AND IMMUNOLOGY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Technology
10.2.3. By Offering
10.2.4. By Application
10.2.5. By End User
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Offering
10.3.1.2.4. By Application
10.3.1.2.5. By End User
10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Offering
10.3.2.2.4. By Application
10.3.2.2.5. By End User
10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Offering
10.3.3.2.4. By Application
10.3.3.2.5. By End User
10.3.4. Turkey Flow Cytometry in Oncology and Immunology Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Type
10.3.4.2.2. By Technology
10.3.4.2.3. By Offering
10.3.4.2.4. By Application
10.3.4.2.5. By End User
10.3.5. Egypt Flow Cytometry in Oncology and Immunology Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Type
10.3.5.2.2. By Technology
10.3.5.2.3. By Offering
10.3.5.2.4. By Application
10.3.5.2.5. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.1.1. Rising Prevalence of Cancer Cases
11.1.2. Advancement in Technology
11.1.3. Recent Developments & Product Launches
11.2. Challenges
11.2.1. High Cost of the Products of the Flow Cytometry Equipment
11.2.2. False antibody responses
12. MARKET TRENDS & DEVELOPMENTS
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.5.1. Danaher Corporation
13.5.2. Merck KGaA
13.5.3. Miltenyi Biotec
13.5.4. Neo-Genomics Laboratories, Inc.
13.5.5. Thermo Fisher Scientific Inc
13.5.6. Cell Signaling Technology, Inc
13.5.7. Becton, Dickinson and Company
13.5.8. Agilent Technologies, Inc.
13.5.9. DiaSorin S.p.A (Luminex Corporation)
13.5.10. OPKO Health, Inc.
14. STRATEGIC RECOMMENDATIONS
